OncoMatch/Clinical Trials/NCT06284486
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Is NCT06284486 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Venetoclax and Revumenib for acute myeloid leukemia.
Treatment: Venetoclax · Revumenib — To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: KMT2A (MLL) rearrangement
Required: NPM1 mutation
Required: NUP98 rearrangement
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
ECOG performance status of ≤ 2 (if aged ≥18 years); Karnofsky Performance Scale of ≥50 (if aged ≥16 years and <18 years); Lansky Performance Score of ≥50 (if aged <16 years)
Prior therapy
Must have received: high intensity chemotherapy — first remission
first remission following high intensity chemotherapy
Must have received: hypomethylating agent — first remission
at least 2 cycles of low intensity therapy (e.g. hypomethylating agent or low-dose cytarabine-based)
Must have received: low-dose cytarabine-based — first remission
at least 2 cycles of low intensity therapy (e.g. hypomethylating agent or low-dose cytarabine-based)
Cannot have received: menin inhibitor
Prior treatment with a menin inhibitor
Lab requirements
Kidney function
estimated glomerular filtration rate ≥ 60 ml/min based on local institutional practice for age-appropriate determination
Liver function
direct bilirubin < 1.5x uln unless increase is due leukemic involvement, and ast and/or alt < 3x uln unless considered due to leukemic involvement, in which case direct bilirubin or ast and/or alt < 5x uln will be considered eligible
Cardiac function
baseline ejection fraction must be > 40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins University · Baltimore, Maryland
- Dana-Farber Cancer Center · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify